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Background: Vitamin and mineral supplement use after a breast cancer diagnosis is common and controversial.
Dosages used and the timing of initiation and/or discontinuation of supplements have not been clearly described.
Methods: We prospectively examined changes in use of 17 vitamin/mineral supplements in the first six months
following breast cancer diagnosis among 2,596 members (28% non-white) of Kaiser Permanente Northern California.
We used multivariable logistic regression to examine demographic, clinical, and lifestyle predictors of initiation and
discontinuation.
Results: Most women used vitamin/mineral supplements before (84%) and after (82%) diagnosis, with average doses
far in excess of Institute of Medicine reference intakes. Over half (60.2%) reported initiating a vitamin/mineral following
diagnosis, 46.3% discontinuing a vitamin/mineral, 65.6% using a vitamin/mineral continuously, and only 7.2% not using
any vitamin/mineral supplement before or after diagnosis. The most commonly initiated supplements were calcium
(38.2%), vitamin D (32.01%), vitamin B6 (12.3%) and magnesium (11.31%); the most commonly discontinued
supplements were multivitamins (17.14%), vitamin C (15.97%) and vitamin E (45.62%). Higher education, higher intake
of fruits/vegetables, and receipt of chemotherapy were associated with initiation (p-values <0.05). Younger age and
breast-conserving surgery were associated with discontinuation (p-values <0.05).
Conclusions: In this large cohort of ethnically diverse breast cancer patients, high numbers of women used vitamin/
mineral supplements in the 6 months following breast cancer diagnosis, often at high doses and in combination with
other supplements. The immediate period after diagnosis is a critical time for clinicians to counsel women on
supplement use.
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American women, especially those diagnosed with cancer,
commonly use dietary supplements [1,2]. Recent studies
have reported that 36-87% of U.S. breast cancer survivors
regularly take a form of vitamin or mineral supplement fol-
lowing diagnosis [3-12], with use more common among
women who are older [12] or have more education [8].* Correspondence: hg2120@columbia.edu
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unless otherwise stated.Common reasons for use include the belief that it will in-
crease tolerance to conventional treatment, alleviate treat-
ment side effects, manage hot flashes, boost immune
function, and promote general health [13].
The efficacy of supplement use for improvement of
health outcomes following a breast cancer diagnosis re-
mains unclear. The majority of studies have not found
dietary supplements to improve breast cancer prognosis
[5,14,15], with some showing benefit [4,6,16] and some
showing harm [4]. Controversy exists regarding use of
antioxidant supplements during treatment due to poten-
tial interactions with conventional therapy [17,18] and lackal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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study showed that patient and physician discussions about
supplement use following a breast cancer diagnosis is un-
common [19].
Many prior studies examining the association between
supplement use pre- and post-cancer diagnosis with
cancer-related outcomes have had methodological limi-
tations. These limitations included lack of detailed pro-
spective data on supplement use, specifically around the
time of diagnosis and treatment, as well as lack of data
collection on changes in supplement use over time. In
addition, supplement use prior to diagnosis is often not
assessed and may confound associations between later
supplement use and cancer outcomes [6].
We examined change in use of vitamin and mineral
supplements within the first six months following breast
cancer diagnosis in a prospective cohort of breast cancer
survivors in Kaiser Permanente Northern California.
Methods
Participants
The Pathways Study is a prospective study of women with
newly diagnosed invasive breast cancer who are members
of Kaiser Permanente Northern California (KPNC), a large,
integrated health care delivery system covering the San
Francisco-Oakland Bay Area, Sacramento, and surrounding
counties. Recruitment was from January 2006 to April 2013
through rapid case ascertainment procedures designed to
enroll women prior to initiation of chemotherapy, as
described elsewhere [20]. Briefly, cases were ascertained
through daily scanning of computerized pathology records
for any new patients with recently diagnosed breast cancer
(usually within 2 months). Participation was restricted to
KPNC female members at least 21 years of age; had no pre-
vious history of malignancy other than non-melanoma skin
cancer; spoke English, Spanish, Cantonese, or Mandarin;
and resided within a 65-mile radius of a field interviewer.
The study was approved by the Columbia University Insti-
tutional Review Board; the Kaiser Permanente Northern
California Institutional Review Board; the University of
California, San Francisco Committee on Human Re-
search; and the Roswell Park Cancer Institute Institu-
tional Review Board.
Breast cancer diagnosis and patient notification of diag-
nosis were verified through manual review of electronic
records, and passive physician consent was obtained prior
to participant recruitment. Written informed consent was
obtained from all participants at the baseline interview.
Participation rates and reasons for refusal have been
described previously [20]. Potentially eligible women (n =
11,233) were invited to participate in the study, and 4,505
enrolled (approximately 47%) after taking into account
number of ineligibles, no contacts, and refusals). Primary
reasons for refusal include being uninterested, too busy,too tired, other health issues, feeling overwhelmed, and/or
participation in another study. Analyses presented here in-
clude 2,596 women who completed both the baseline and
six-month follow-up questionnaires as of February 19,
2014, had a record in the KPNC Cancer Registry as of
June December 31, 2012, and specified their race/ethni-
city. The mean time from diagnosis to enrollment was 2.0
(±0.7) months, and from enrollment to follow-up 6.0
(±1.0) months.
Measures
Clinical and diagnostic tumor characteristics were ob-
tained from the KPNC Cancer Registry approximately
four months post-diagnosis. These included: AJCC stage
at diagnosis, number of positive nodes, estrogen/progester-
one receptor positivity, HER2/neu status, surgery type, and
treatments received. The baseline interview was conducted
at enrollment approximately two months post-diagnosis
and included interviewer and self-administered question-
naires on sociodemographics, diet, physical activity, smok-
ing, established breast cancer risk factors, health history,
and use of vitamin/mineral supplements. Anthropometric
measures were also obtained at baseline. Six months after
the baseline interview, a packet of follow-up materials soli-
citing the same information collected at baseline was
mailed to the participant’s home, with interviewer assist-
ance offered if needed.
Assessment of change in vitamin/mineral
supplement intake
At baseline and the six month follow-up, each participant
was asked about multivitamins and single formulations
taken at least once a week for a month or longer, with con-
tainer labels being referenced if available. Women were first
asked whether they had ever taken each type of supple-
ment. For those reporting ever use of a particular supple-
ment, consumption prior to breast cancer diagnosis was
assessed for each single supplement by asking, “Did you
take (vitamin/mineral) before you were diagnosed?” and for
multivitamins by asking, “How many times per week did
you take the multivitamin before your diagnosis?” Detailed
information was then obtained regarding dose, frequency
and duration of use. Multivitamin dose was assessed using
the number of pills taken each time for multivitamins. Sin-
gle supplement dose categories were based on common
doses used in store-bought formulations.
Baseline and follow-up questionnaire responses were
used to establish supplement use during the two time pe-
riods of interest: 1) prior to diagnosis and 2) between base-
line and the six-month follow-up interview. Use after
diagnosis was defined as any yes response during the period
between the baseline and six-month follow-up interviews.
These data were used to identify four classifications of users
for each supplement: initiators, discontinuers, continuous
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ments after baseline but not prior to diagnosis. Disconti-
nuers were defined as those reporting use before diagnosis
but not at any time between baseline and the follow-up
interview. Continuous users were those using the specified
supplement both before diagnosis and at any point between
baseline and follow-up. Non-users reported no use prior to
or following diagnosis.
Baseline assessment of diet and physical activity
Diet was assessed using a 139-item modified version of
the Block 2005 food frequency questionnaire (Nutrition-
Quest, Berkeley, CA). Food items were selected by identi-
fying the top population contributors of each nutrient
among whites, African Americans, and Hispanics in the
National Health and Nutrition Examination Survey (1999-
2002) [21,22]. Physical activity was assessed with an activ-
ity frequency questionnaire based on the Arizona Activity
Frequency Questionnaire [23].
Statistical analyses
Bivariate analyses of ever use of vitamin/mineral supple-
ments, stratified by race/ethnicity, were performed using
Pearson’s chi-squared test. Next, the frequencies of never
use, continuous use, initiating, and discontinuing were cal-
culated for each supplement. To better understand patterns
of use in continuous users, mean doses were established for
each supplement, and changes in dose were computed by
subtracting the average daily dose prior to diagnosis from
the average daily dose reported at the six-month follow-up.
Compared to baseline, a positive or negative value indicates
an increase or decrease in dose at follow-up, respectively.
Student’s t-tests were used to examine differences in dose
between continuous users and initiators or discontinuers.
Doses for initiators were compared with doses for continu-
ous users at the six-month follow-up, whereas doses for
discontinuers were compared with doses of continuous
users prior to diagnosis.
Multivariable logistic regression was performed to ex-
plore predictors of initiation, discontinuation, and continu-
ous use of multivitamins, vitamin C, vitamin D, vitamin E
and calcium, which were the most commonly used. Models
were adjusted for age, race, education, household income,
family history of breast cancer, stage at diagnosis, number
of positive lymph nodes, hormone receptor positivity,
HER2/neu status, surgery type, treatment received, BMI,
fruit/vegetable intake, physical activity and smoking status.
Prior use of vitamins/minerals was not included as a co-
variate in the models due to the possibility of spurious as-
sociations between predictors of interest and change in
supplement use. Odds ratios (OR) and 95% confidence in-
tervals (CI) for initiation were calculated among non-users
prior to diagnosis. Similarly, among supplement users
prior to diagnosis, the odds of discontinuing by the six-month follow-up questionnaire were calculated. All p-
values were two-tailed with a significance level of 0.05.
Results
Participant characteristics
Demographic and clinical characteristics for women com-
pleting both the baseline and six-month questionnaires
are presented in Table 1. Study participants represent an
ethnically diverse population: 71.5% non-Hispanic whites,
11.9% Asians, 10.6% Hispanics, and 6.0% African Ameri-
cans. The median age at diagnosis was 61.1 ± 11.8 years,
and the average education level was college graduate.
Most participants had either stage I (56.2%) or stage II
(33.0%) breast cancer at diagnosis, and the majority had
tumors positive for both estrogen and progesterone recep-
tors (64.1%).
Overall vitamin/mineral supplement use
Most women (83.6%) reported using at least one vitamin/
mineral supplement prior to diagnosis, with the most
common being multivitamins (70.0%) (Table 1). Prior to
diagnosis, vitamin C, calcium, and vitamin E were each
used by over 20% of women, and vitamin D was used by
15.4% of women. Vitamin/mineral supplement use prior
to diagnosis was highest among non-Hispanic whites
(85.9%) and lowest among Hispanics (73.8%).
Changes in vitamin/mineral supplement use
At the six-month follow-up, 82.0% of the study population
reported using at least one vitamin/mineral supplement
following diagnosis with breast cancer (Table 1). Over half
(60.2%) of women reported initiating a vitamin/mineral
following diagnosis, 46.3% reported discontinuing a vita-
min/mineral, 65.5% reported using a vitamin/mineral con-
tinuously, and only 7.2% reported not using any vitamin/
mineral supplement before or after diagnosis (data not
shown). Figure 1 shows the number of initiators, disconti-
nuers, continuous users and never users for each type of
vitamin/mineral supplement. Calcium (38.2%), vitamin D
(32.0%), magnesium (11.3%), and vitamin B6 (10.1%) were
the most commonly initiated supplements. Multivitamins
(17.1%), vitamin C (16.0%), vitamin E (14.6%), calcium
(9.2%), iron (9.8%), and folic acid (5.7%) were the most
commonly discontinued supplements. Multivitamins
(53.6%), vitamin C (16.9%), calcium (14.6%), and vitamin D
(12.2%) were the most commonly used continuously from
the period before diagnosis through the 6-month follow-up.
Doses of vitamin/mineral supplements
Doses of nearly all vitamin/mineral supplements were
far in excess of the Institute of Medicine’s (IOM) Dietary
Reference Intakes [24] (Table 2). Among continuous users,
there were notable increases in the mean consumption
of vitamin D (33.8%), magnesium (18.1%) and calcium
Table 1 Baseline demographic characteristics, clinical characteristics and use of vitamin/mineral supplements prior to
diagnosis, by race, Kaiser Permanente Northern California, 2006-2013 (n = 2,596a)
All
(n = 2,596) %
Non-Hispanic White
(n = 1,857) %
African American
(n = 155) %
Asian
(n = 309) %
Hispanic




<50 18.5 13.0 19.4 39.5 31.3
50-59 26.7 24.8 35.5 30.4 29.8
60-69 31.9 35.2 27.7 22.7 22.9
70+ 23.0 27.0 17.4 7.4 16.0
Education <.0001
High school or less 13.6 11.8 19.4 8.1 28.4
Some college 33.4 35.1 42.6 14.9 37.8
College graduate 28.4 26.7 22.6 49.5 19.6
Post graduate 24.5 26.3 15.5 27.5 14.2
Clinical characteristics
Stage at diagnosis 0.13
I 56.2 57.3 50.3 54.7 54.2
II 33.0 32.2 37.4 35.0 34.2
III 9.6 9.4 9.0 10.0 11.3
IV 1.1 1.2 3.2 0.32 0.36
Hormone-receptor positivity <.0001
ER-/PR- 15.7 13.9 29.0 17.2 18.2
ER-/PR+ 0.12 0.05 0.0 0.0 0.73
ER+/PR- 20.0 21.1 22.6 15.5 16.0
ER+/PR+ 64.1 64.8 47.7 67.3 65.1
Unknown 0.15 0.16 0.65 0.0 0.0
Use of vitamin/mineral supplements prior to diagnosis
Any vitamin/mineral 83.6 85.9 82.6 78.3 73.8 <.0001
Multivitamins 70.0 73.0 66.5 64.7 58.2 <.0001
Vitamin C 32.3 34.7 27.7 26.5 24.7 0.0003
Calcium, tums, or antacids with calcium 23.6 25.1 20.6 21.4 17.8 0.03
Vitamin E 21.9 23.4 22.6 17.2 16.7 0.01
Vitamin D 15.4 16.0 20.0 10.4 14.5 0.02
Iron 12.2 11.5 24.5 10.4 12.4 <.0001
Vitamin B12 9.6 9.4 16.1 6.5 11.3 0.007
Folic acid (folate) 8.4 8.9 9.7 6.5 6.9 0.36
Magnesium 5.2 5.7 5.8 1.6 5.5 0.03
Zinc 4.7 5.2 3.2 2.9 4.0 0.24
Vitamin A 3.2 3.1 4.5 1.6 4.7 0.13
Chromium 2.7 2.7 2.6 1.9 4.0 0.49
Niacin (B3) 2.0 2.2 1.9 1.0 1.8 0.58
Beta carotene 1.7 2.0 0.6 0.6 1.1 0.19
Selenium 1.8 2.2 1.9 0.3 1.5 0.16
Thiamin (B1) 0.8 0.9 0.0 0.6 1.1 0.64
Greenlee et al. BMC Cancer 2014, 14:382 Page 4 of 16
http://www.biomedcentral.com/1471-2407/14/382
Table 1 Baseline demographic characteristics, clinical characteristics and use of vitamin/mineral supplements prior to
diagnosis, by race, Kaiser Permanente Northern California, 2006-2013 (n = 2,596a) (Continued)
Use of vitamin/mineral supplements after diagnosis
Any vitamin/mineral 82.0 84.7 79.4 77.3 71.3 <.0001
Multivitamins 60.8 63.6 51.6 57.6 50.5 <.0001
Vitamin C 24.7 26.5 18.1 22.3 18.9 0.003
Calcium, tums, or antacids with calcium 51.8 56.2 38.7 44.0 38.5 <.0001
Vitamin E 11.6 12.8 7.7 7.8 10.5 0.02
Vitamin D 43.1 45.4 40 36.2 37.5 0.003
Iron 7.5 6.9 14.8 7.4 7.0 0.009
Vitamin B12 13.8 14.6 16.1 10.4 11.3 0.11
Folic acid (folate) 9.1 10.1 7.1 5.8 7.3 0.04
Magnesium 13.8 15.6 7.1 10.0 10.2 0.0004
Zinc 7.6 8.6 5.2 6.5 3.6 0.01
Vitamin A 3.1 3.2 1.9 2.6 3.3 0.75
Chromium 3.0 3.2 1.9 2.3 2.9 0.66
Niacin (B3) 7.4 8.3 5.2 4.5 5.5 0.03
Beta carotene 1.7 1.9 0.65 1.6 1.5 0.67
Selenium 3.1 3.5 1.9 1.9 2.2 0.27
Thiamin (B1) 6.5 7.1 3.9 5.5 5.8 0.31
aAmong Pathways participants with both baseline and 6 month follow up questionnaire.
bCalculated using a chi-squared test.
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and beta-carotene (21.1%). On average, continuous users
consumed higher doses of supplements than initiators or
discontinuers for most supplements, although doses were
















































































Figure 1 Change in supplement use from breast cancer diagnosis to
figure displays the percent of participants who were never users (blue), con
the time of breast cancer diagnosis to 6 months post diagnosis.Predictors of supplement initiation, discontinuation and
continuous use
Tables 3, 4 and 5 show ORs and 95% CIs from
multivariable-adjusted models for initiation, discontinu-






































































6 months post diagnosis. For each type of dietary supplement, this
tinuous users (yellow), discontinuers (red) and initiators (green) from
Table 2 Change in vitamin/mineral supplement daily dose from diagnosis to 6 monthsa
Initiatorsb Discontinuersc Continuous users
IOM reference
intakesd
Change in dose from
diagnosis to 6 months
P-
valuee
Change in dose from









Multivitamins (pills) n/a 1.45 0.53 −1.32 0.34 1.39 1.23 −0.17
Vitamin C (mg) 75 mg 615.95 0.01 −557.97 <.0001 780.10 740.57 −26.07
Calcium (mg) 1200 mg 859.31 <.0001 −743.69 0.56 704.55 815.69 119.70
Vitamin E (IU) 15 mcgh 280.89 <.0001 −391.09 0.66 400.97 357.97 −41.32
Vitamin D (IU) 600 mcgg 1064.94 <.0001 −2505.33 0.26 1800.20 2306.79 609.09
Iron (mg) 8 mg 184.13 0.56 −80.08 0.38 129.99 79.66 −73.85
Vitamin B12 (mcg) 2.4 mcg 245.80 <.0001 −612.35 0.18 794.29 625.99 −126.84
Folic acid (folate) (mcg) 400 mcg 416.38 <.0001 −475.81 0.05 616.75 552.73 −42.47
Magnesium (mg) 320 mg 289.02 0.91 −315.55 0.62 293.46 319.25 57.69
Zinc (mg) 8 mg 12.79 <.0001 −17.56 0.004 42.14 38.08 4.46
Vitamin B6 (mg) 1.3-1.5 mg 63.77 0.07 −110.61 0.56 88.96 91.34 −16.14
Vitamin A (IU) 700 mcgi,h 5966.11 0.02 −11113.52 0.93 10736.26 7283.16 −3425.60
Chromium (mg) 0.02 mg 165.46 0.03 −176.16 0.09 280.96 284.16 13.65
Niacin (B3) (mg) 14 mg 167.02 <.0001 −368.21 0.02 850.00 915.86 94.52
Beta carotene (IU) 12552.93 0.10 −12750.00 0.15 19722.22 13437.50 −4166.67
Selenium (mcg) 55 mg 101.96 0.11 −111.01 0.21 144.25 137.41 −1.28
Thiamin (B1) (mg) 1.1 mg 57.81 0.07 −28.35 0.17 164.06 179.76 57.14
aOrdered by prevalence of use prior to diagnosis.
bInitiators defined as those taking supplements at six-month follow-up but not at baseline visit.
cDiscontinuers defined as those taking supplements at baseline but not at six-month follow-up visit.
dBased on Institute of Medicine Recommended Dietary Allowances and Adequate Intakes for females age 51 years and older.
eT-test comparing 6 months dose to baseline dose of Continuous Users.
fT-test comparing diagnosis dose to diagnosis dose of Continuous Users.
gThe amount of change may not reflect the apparent difference between diagnosis and 6 months since both measures are required in order to be included.
hIOM recommended dietary allowances for vitamins A, D, and E are expressed in micrograms, while the study values are international units (I.U.).
iThe IOM recommended dietary allowance of 700 mcg vitamin A is expressed in retinol activity equivalents (RAE), where 1 RAE = 1 mcg retinol or 12 mcg beta-carotene.
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women who were and were not using the specific sup-
plement prior to diagnosis, respectively.Demographics
Women over age 50 years were more likely to initiate vita-
min D and calcium; continue to use calcium, vitamin E,
and vitamin D; and less likely to initiate vitamin E or dis-
continue multivitamin supplements. Race was not strongly
associated with supplement use. Higher education pre-
dicted both initiating and not discontinuing multivitamins.
Higher household income was associated with not initiat-
ing multivitamins, discontinuing vitamin E, and continu-
ously using multivitamins and vitamin D.Clinical characteristics
Family history of breast cancer and several clinical charac-
teristics, including stage, number of positive nodes, and
hormone receptor status, were not associated with supple-
ment initiation, although there was a trend against initiat-
ing multivitamins among those with higher stage tumors.There were few consistencies observed across treatment
groups. Examining supplement use by treatments re-
ceived, individuals undergoing chemotherapy were less
likely to initiate the antioxidants vitamin C and vitamin E,
continue use of vitamin D, and more likely to discontinue
multivitamins. Individuals undergoing both chemotherapy
and radiation were less likely to continue using multivita-
mins. There were differences in supplement use between
women who had different surgical procedures. Among
women who had a mastectomy, there was a trend toward
continuing rather than discontinuing most supplements.
Lifestyle factors
Neither BMI nor physical activity was consistently associ-
ated with initiating or discontinuing supplement use.
Women consuming higher amounts of fruits/vegetables
were more likely to initiate vitamin C, vitamin D, and cal-
cium, but not vitamin E or multivitamins.
Discussion
In a large prospective cohort study of women in North-
ern California diagnosed with first primary breast cancer,
Table 3 Predictors of initiating vitamin/mineral supplement use by the 6-month follow up
Covariates Multivitamins (n = 751) Vitamin C (n = 1,661) Calcium (n = 1,941) Vitamin E (n = 1,897) Vitamin D (n = 2,129)
OR 95% CI P-value OR 95% CI P-value OR 95% CI P-value OR 95% CI P-value OR 95% CI P-value
Age
<50 years Ref Ref Ref Ref Ref
50-59 years 1.03 0.59, 1.81 0.97 0.78 0.48, 1.25 0.30 2.56 1.84, 3.55 <.0001 0.68 0.37, 1.26 0.22 1.82 1.34, 2.48 .0001
60-69 years 0.62 0.34, 1.14 0.13 0.92 0.56, 1.49 0.72 3.01 2.13, 4.23 <.0001 0.42 0.22, 0.83 0.01 2.19 1.59, 3.02 <.0001
70+ years 0.68 0.32, 1.42 0.30 0.98 0.56, 1.74 0.95 3.08 2.06, 4.60 <.0001 0.45 0.21, 0.97 0.04 2.02 1.38, 2.95 .0003
Race
Non-Hispanic white Ref Ref Ref Ref Ref
African American 0.69 0.30, 1.30 0.39 0.76 0.36, 1.61 0.47 0.72 0.45, 1.16 0.17 0.75 0.28, 2.01 0.56 0.89 0.55, 1.43 0.63
Asian 0.91 0.47, 1.75 0.77 1.61 0.99, 2.62 0.05 0.83 0.58, 1.19 0.31 1.07 0.52, 2.21 0.85 0.87 0.62, 1.23 0.43
Hispanic 0.85 0.46, 1.56 0.60 0.77 0.38, 1.26 0.23 0.58 0.40, 0.83 0.004 1.20 0.60, 2.41 0.61 0.96 0.68, 1.37 0.83
Education
Highschool or less Ref Ref Ref Ref Ref
Some college 2.58 1.35, 4.94 0.004 1.09 0.63, 1.91 0.75 0.91 0.64, 1.29 0.59 1.51 0.66, 3.45 0.33 0.84 0.58, 1.13 0.22
College graduate 1.61 0.78, 3.29 0.20 1.62 0.92, 2.86 0.10 1.14 0.79, 1.65 0.49 2.06 0.88, 4.83 0.10 1.00 0.70, 1.41 0.98
Post graduate 2.80 1.35, 5.78 0.006 0.99 0.53, 1.83 0.62 1.23 0.84, 1.81 0.30 2.11 0.87, 5.12 0.10 1.11 0.77, 1.60 0.59
Household income
≤$25,000 Ref Ref Ref Ref Ref
$25,000-49,999 0.43 0.23, 0.82 0.01 1.12 0.59, 2.13 0.73 1.21 0.81, 1.82 0.35 0.93 0.40, 2.17 0.87 1.18 0.79, 1.75 0.42
$50,000-89,999 0.25 0.13, 0.49 <.0001 1.28 0.69, 2.36 0.44 1.37 0.92, 2.03 0.12 1.04 0.46, 2.33 0.93 1.35 0.91, 2.0 0.13
$90,000+ 0.29 0.15, 0.56 .0003 1.25 0.66, 2.36 0.49 1.49 0.99, 2.26 0.06 0.53 0.22, 1.28 0.16 1.22 0.81, 1.82 0.34
Family history of breast cancer
No Ref Ref Ref Ref Ref
Yes 0.97 0.60, 1.57 0.91 1.17 0.80, 1.70 0.43 0.98 0.75, 1.26 0.86 1.54 0.95, 2.50 0.08 0.97 0.76, 1.24 0.80
Stage at diagnosis
I Ref Ref Ref Ref Ref
II 1.0 0.54, 1.85 1.0 0.77 0.46, 1.28 0.31 0.71 0.51, 0.97 0.03 0.94 0.48, 1.84 0.86 0.88 0.65, 1.19 0.40
III+ 0.50 0.12, 2.08 0.34 1.33 0.46, 3.82 0.59 0.49 0.23, 1.05 0.07 2.09 0.53, 8.30 0.30 0.65 0.31, 1.38 0.26
Number of positive nodes
None Ref Ref Ref Ref Ref
1-3 1.08 0.55, 2.1 0.82 1.47 0.82, 2.62 0.20 0.97 0.67, 1.41 0.89 1.15 0.52, 2.56 0.73 0.99 0.70, 1.42 0.97


















Table 3 Predictors of initiating vitamin/mineral supplement use by the 6-month follow up (Continued)
Hormone-receptor positivity
ER- and PR - Ref Ref Ref Ref Ref
ER + and/or PR+ 1.14 0.63, 2.06 0.66 1.19 0.70, 2.01 0.52 1.26 0.91, 1.73 0.17 1.25 0.60, 2.59 0.55 1.38 1.01, 1.88 0.04
HER2/Neu status
Negative Ref Ref Ref Ref Ref
Positive 1.11 0.57, 2.16 0.76 1.12 0.67, 1.88 0.66 0.69 0.50, 0.97 0.03 0.62 0.27, 1.42 0.26 1.05 0.76, 1.43 0.78
Not performed 0.96 0.29, 2.93 0.89 1.56 0.69, 3.54 0.29 1.93 1.0, 3.71 0.05 1.73 0.65, 4.60 0.27 2.11 1.21, 3.69 0.009
Surgery type
Conserving or none Ref Ref Ref Ref Ref
Mastectomy 1.12 0.67, 1.89 0.67 0.86 0.56, 1.32 0.48 1.09 0.81, 1.46 0.57 1.03 0.56, 1.88 0.93 1.22 0.93, 1.60 0.15
Treatment status
None Ref Ref Ref Ref Ref
Chemotherapy only 1.08 0.53, 2.20 0.84 0.55 0.31, 0.96 0.03 0.89 0.62, 1.28 0.53 0.45 0.21, 0.96 0.04 0.71 0.50, 1.0 0.05
Radiation only 1.22 0.61, 2.41 0.57 0.72 0.43, 1.21 0.22 1.14 0.72, 1.51 0.83 0.87 0.43, 1.75 0.69 1.02 0.73, 1.43 0.90
Both 0.94 0.42, 2.10 0.88 0.67 0.35, 1.29 0.23 0.89 0.57, 1.39 0.60 0.46 0.18, 1.18 0.10 0.75 0.50, 1.15 0.19
BMI
<25 kg/m2 Ref Ref Ref Ref Ref
25-30 kg/m2 0.68 0.42, 1.09 0.11 0.98 0.67, 1.45 0.93 0.81 0.63, 1.05 0.10 1.21 0.72, 2.05 0.47 0.86 0.67, 1.09 0.20
>30 kg/m2 1.04 0.63, 1.72 0.88 1.39 0.92, 2.09 0.12 0.81 0.61, 1.07 0.14 1.53 0.88, 2.67 0.13 0.96 0.74, 1.24 0.74
Fruit and vegetable intake
<35 servings/week Ref Ref Ref Ref Ref
≥35 servings/week 1.14 0.76, 1.72 0.52 1.42 1.02, 1.97 0.04 1.60 1.28, 1.99 <.0001 0.91 0.58, 1.42 0.68 1.48 1.20, 1.83 .0002
Hrs/wk of moderate-vigorous activity
<2.5 Ref Ref Ref Ref Ref
2.5 - 5 0.89 0.52, 1.52 0.56 1.05 0.68, 1.64 0.82 1.42 1.06, 1.93 0.02 1.05 0.54, 2.07 0.88 1.27 0.96, 1.69 0.10
>5 0.89 0.55, 1.43 0.74 0.94 0.64, 1.39 0.77 1.18 0.91, 1.54 0.27 1.69 0.98, 2.91 0.06 1.17 0.91, 1.50 0.23
Smoking status
Never Ref Ref Ref Ref Ref
Ever 1.19 0.79, 1.78 0.40 1.40 1.0, 1.95 0.05 1.40 1.12, 1.74 0.003 1.61 1.03, 2.52 0.04 1.0 0.81, 1.23 0.96
aAmong Pathways participants with both baseline and 6 month follow up questionnaire and who were users prior to breast cancer diagnosis.
bBeta Carotene not included in the table because insufficient number of users prior to diagnosis (n = 20).


















Table 4 Predictors of discontinuing vitamin/mineral supplement use by the 6-month follow up
Covariates Multivitamins (n = 1,563) Vitamin C (n = 723) Calcium (n = 542) Vitamin E (n = 496) Vitamin D (n = 287)
OR 95% CI P-value OR 95% CI P-value OR 95% CI P-value OR 95% CI P-value OR 95% CI P-value
Age
<50 years Ref Ref Ref Ref Ref
50-59 years 0.73 0.52, 1.04 0.08 0.81 0.48, 1.38 0.44 0.51 0.28, 0.93 0.03 0.87 0.39, 1.92 0.72 0.69 0.22, 2.13 0.52
60-69 years 0.58 0.40, 0.85 0.005 0.98 0.58, 1.67 0.94 0.59 0.32, 1.08 0.09 0.73 0.33, 1.60 0.43 0.45 0.14, 1.42 0.17
70+ years 0.37 0.23, 0.56 <.0001 1.26 0.69, 2.30 0.46 0.73 0.36, 1.46 0.37 0.77 0.32, 1.85 0.56 0.86 0.25, 2.92 0.81
Race
Non-Hispanic white Ref Ref Ref Ref Ref
African American 1.38 0.82, 2.31 0.22 1.83 0.86, 3.89 0.12 1.77 0.75, 4.16 0.19 1.93 0.72, 5.19 0.19 0.70 0.18, 2.70 0.61
Asian 0.86 0.56, 1.31 0.48 1.71 0.92, 3.16 0.09 1.71 0.87, 3.37 0.12 1.48 0.60, 3.63 0.40 1.58 0.51, 4.89 0.43
Hispanic 1.18 0.76, 1.84 0.45 0.99 0.54, 1.82 0.97 0.88 0.43, 1.80 0.73 0.80 0.37, 1.74 0.57 3.07 1.19, 7.94 0.02
Education
High School or less Ref Ref Ref Ref Ref
Some college 0.60 0.40, 0.90 0.01 1.47 0.84, 2.55 0.18 1.32 0.66, 2.63 0.44 1.33 0.68, 2.61 0.41 2.17 0.67, 6.99 0.20
College graduate 0.56 0.37, 0.87 0.01 1.17 0.65, 2.10 0.61 0.57 0.27, 1.18 0.13 0.68 0.33, 1.39 0.29 1.05 0.31, 3.58 0.94
Post graduate 0.60 0.39, 0.94 0.03 1.29 0.71, 2.33 0.40 1.10 0.54, 2.26 0.79 0.91 0.44, 1.89 0.80 0.73 0.21, 2.50 0.61
Household income
≤$25,000 Ref Ref Ref Ref Ref
$25,000-49,999 1.21 0.72, 2.04 0.47 1.20 0.63, 2.31 0.58 0.46 0.20, 1.05 0.06 1.60 0.76, 3.36 0.21 1.80 0.56, 5.75 0.32
$50,000-89,999 0.88 0.53, 1.47 0.63 1.38 0.72, 2.63 0.33 0.50 0.22, 1.11 0.09 2.39 1.15, 4.95 0.02 0.88 0.28, 2.78 0.82
$90,000+ 0.94 0.56, 1.60 0.83 2.43 1.24, 4.78 0.01 0.74 0.32, 1.68 0.46 2.91 1.35, 6.25 0.01 0.81 0.25, 2.67 0.73
Family history of breast cancer
No Ref Ref Ref Ref Ref
Yes 0.93 0.69, 1.27 0.65 0.88 0.60, 1.30 0.51 0.67 0.41, 1.08 0.10 1.18 0.71, 1.94 0.53 0.82 0.38, 1.77 0.61
Stage at diagnosis
I Ref Ref Ref Ref Ref
II 1.05 0.72, 1.52 0.81 0.89 0.55, 1.44 0.64 0.69 0.37, 1.29 0.24 0.82 0.42, 1.60 0.56 1.01 0.37, 2.79 0.98
III+ 1.69 0.75, 3.83 0.21 1.77 0.49, 6.38 0.39 0.33 0.07, 1.52 0.16 0.45 0.08, 2.53 0.36 1.97 0.21, 18.57 0.55
Number of positive nodes
None Ref Ref Ref Ref Ref
1-3 1.12 0.73, 1.71 0.60 1.17 0.66, 2.07 0.59 1.35 0.67, 2.73 0.40 1.27 0.58, 2.79 0.56 1.50 0.45, 5.00 0.51


















Table 4 Predictors of discontinuing vitamin/mineral supplement use by the 6-month follow up (Continued)
Hormone-receptor positivity
ER- and PR - Ref Ref Ref Ref Ref
ER + and/or PR+ 0.80 0.56, 1.14 0.21 0.76 0.48, 1.21 0.25 0.74 0.43, 1.29 0.29 1.30 0.69, 2.45 0.42 0.68 0.28, 1.62 0.38
HER2/Neu status
Negative Ref Ref Ref Ref Ref
Positive 1.04 0.73, 1.49 0.81 1.31 0.78, 2.20 0.31 0.61 0.33, 1.13 0.12 0.79 0.40, 1.58 0.50 0.92 0.32, 2.63 0.88
Not performed 1.46 0.76, 2.80 0.26 0.80 0.33, 1.97 0.63 0.90 0.32, 2.54 0.84 0.87 0.24, 3.12 0.83 0.82 0.14, 4.89 0.83
Surgery type
Conserving or none Ref Ref Ref Ref Ref
Mastectomy 0.94 0.68, 1.29 0.69 0.59 0.38, 0.90 0.01 0.71 0.43, 1.17 0.18 0.58 0.33, 1.03 0.06 0.66 0.28, 1.54 0.34
Treatment status
None Ref Ref Ref Ref Ref
Chemotherapy only 1.57 1.02, 2.43 0.04 1.71 0.99, 2.97 0.05 1.48 0.74, 2.95 0.26 2.29 1.09, 4.79 0.03 0.97 0.31, 3.08 0.96
Radiation only 1.25 0.81, 1.93 0.32 0.85 0.51, 1.41 0.52 0.76 0.41, 1.42 0.39 0.51 0.27, 0.98 0.04 0.54 0.19, 1.56 0.25
Both 1.05 0.61, 1.81 0.85 1.31 0.67, 2.58 0.43 1.20 0.55, 2.65 0.65 0.99 0.42, 2.32 0.98 2.77 0.92, 8.39 0.07
BMI
<25 kg/m2 Ref Ref Ref Ref Ref
25-30 kg/m2 1.03 0.77, 1.39 0.83 0.78 0.53, 1.14 0.20 1.01 0.62, 1.64 0.97 1.23 0.74, 2.02 0.43 0.65 0.29, 1.46 0.29
>30 kg/m2 0.93 0.67, 1.29 0.68 0.78 0.51, 1.20 0.26 1.53 0.93, 2.52 0.10 1.01 0.57, 1.79 0.97 1.22 0.53, 2.80 0.64
Fruit and vegetable intake
<35 servings/week Ref Ref Ref Ref Ref
≥35 servings/week 0.85 0.66, 1.11 0.23 1.19 0.85, 1.66 0.31 0.70 0.47, 1.04 0.08 0.82 0.54, 1.25 0.36 0.48 0.25, 0.94 0.03
Hrs/wk of moderate- vigorous activity
<2.5 Ref Ref Ref Ref Ref
2.5 - 5 0.71 0.49, 1.04 0.08 1.00 0.62, 1.60 0.99 1.63 0.93, 2.87 0.09 0.80 0.44, 1.46 0.46 1.92 0.77, 4.79 0.16
>5 1.15 0.85, 1.57 0.37 0.82 0.54, 1.24 0.34 1.62 0.99, 2.65 0.06 0.74 0.42, 1.28 0.27 1.05 0.48, 2.27 0.91
Smoking status
Never Ref Ref Ref Ref Ref
Ever 0.95 0.73, 1.23 0.68 0.81 0.58, 1.12 0.20 0.88 0.59, 1.30 0.51 0.70 0.46, 1.08 0.10 0.96 0.49, 1.88 0.90
aAmong Pathways participants with both baseline and 6 month follow up questionnaire and who were non-users prior to breast cancer diagnosis.
bBeta Carotene not included in the table because insufficient number of users prior to diagnosis (n = 20).


















Table 5 Predictors of continuous vitamin/mineral supplement use by the 6-month follow up
Covariates Multivitamins (n = 1,563) Vitamin C (n = 723) Calcium (n = 542) Vitamin E (n = 496) Vitamin D (n = 287)
OR 95% CI P-value OR 95% CI P-value OR 95% CI P-value OR 95% CI P-value OR 95% CI P-value
Age
<50 years Ref Ref Ref Ref Ref
50-59 years 1.28 0.91, 1.8 0.16 1.26 0.84, 1.89 0.27 2.06 1.34, 3.16 0.001 1.78 0.91, 3.48 0.09 2.99 1.65, 5.4 .0003
60-69 years 1.10 0.77, 1.56 0.61 1.27 0.84, 1.92 0.27 2.48 1.6, 3.86 <.0001 2.54 1.32, 4.89 0.01 5.31 2.95, 9.54 <.0001
70+ years 1.51 0.99, 2.31 0.05 1.28 0.8, 2.04 0.30 2.36 1.41, 3.96 0.001 2.35 1.15, 4.79 0.02 7.14 3.75, 13.61 <.0001
Race
Non-Hispanic white Ref Ref Ref Ref Ref
African American 0.66 0.4, 1.08 0.10 0.58 0.32, 1.05 0.07 0.59 0.31, 1.15 0.12 0.57 0.24, 1.4 0.22 2.34 1.3, 4.2 0.005
Asian 0.79 0.54, 1.14 0.21 0.57 0.35, 0.91 0.02 0.61 0.37, 1 0.05 0.47 0.23, 0.98 0.04 0.80 0.46, 1.38 0.42
Hispanic 0.54 0.37, 0.78 0.001 0.73 0.47, 1.12 0.15 0.66 0.42, 1.06 0.09 0.87 0.48, 1.57 0.64 0.99 0.56, 1.75 0.97
Education
High School or less Ref Ref Ref Ref Ref
Some college 1.82 1.27, 2.61 0.001 0.88 0.6, 1.31 0.53 0.97 0.6, 1.55 0.89 0.96 0.56, 1.66 0.89 1.02 0.59, 1.76 0.95
College graduate 1.63 1.11, 2.39 0.01 1.01 0.66, 1.54 0.98 1.38 0.84, 2.25 0.20 1.28 0.72, 2.26 0.40 1.48 0.84, 2.62 0.17
Post graduate 1.90 1.27, 2.85 0.002 1.12 0.73, 1.73 0.60 1.42 0.85, 2.37 0.18 1.12 0.62, 2.02 0.72 2.53 1.44, 4.46 0.001
Household income
≤$25,000 Ref Ref Ref Ref Ref
$25,000-49,999 1.03 0.65, 1.63 0.91 1.38 0.87, 2.17 0.17 2.15 1.17, 3.94 0.01 0.75 0.43, 1.29 0.30 1.08 0.61, 1.9 0.79
$50,000-89,999 1.26 0.81, 1.97 0.30 1.19 0.76, 1.87 0.45 2.13 1.17, 3.88 0.01 0.56 0.33, 0.98 0.04 1.29 0.75, 2.22 0.36
$90,000+ 0.99 0.62, 1.57 0.97 0.74 0.45, 1.2 0.22 2.05 1.1, 3.8 0.02 0.49 0.27, 0.88 0.02 1.36 0.77, 2.41 0.28
Family history of breast cancer
No Ref Ref Ref Ref Ref
Yes 1.05 0.8, 1.39 0.71 1.05 0.78, 1.4 0.77 1.04 0.75, 1.45 0.82 0.86 0.57, 1.3 0.48 1.28 0.91, 1.8 0.17
Stage at diagnosis
I Ref Ref Ref Ref Ref
II 1.11 0.8, 1.56 0.53 1.00 0.69, 1.43 0.98 0.72 0.47, 1.09 0.12 0.97 0.58, 1.62 0.91 0.81 0.52, 1.28 0.37
III+ 2.00 0.81, 4.96 0.14 0.64 0.22, 1.86 0.41 0.74 0.27, 2 0.55 1.58 0.45, 5.53 0.47 0.70 0.23, 2.13 0.53
Number of positive nodes
None Ref Ref Ref Ref Ref
1-3 1.02 0.69, 1.52 0.91 0.88 0.57, 1.37 0.57 0.98 0.6, 1.58 0.92 1.10 0.59, 2.05 0.78 1.27 0.74, 2.18 0.38


















Table 5 Predictors of continuous vitamin/mineral supplement use by the 6-month follow up (Continued)
Hormone-receptor positivity
ER- and PR - Ref Ref Ref Ref Ref
ER + and/or PR+ 1.15 0.83, 1.61 0.41 0.97 0.66, 1.43 0.88 1.22 0.8, 1.85 0.36 0.84 0.5, 1.4 0.49 1.31 0.82, 2.11 0.26
HER2/Neu status
Negative Ref Ref Ref Ref Ref
Positive 1.52 1.05, 2.2 0.03 0.83 0.54, 1.26 0.38 0.99 0.65, 1.5 0.96 1.01 0.58, 1.76 0.97 0.77 0.45, 1.32 0.34
Not performed 0.86 0.45, 1.63 0.64 1.37 0.71, 2.66 0.35 1.90 0.84, 4.32 0.13 0.89 0.34, 2.32 0.81 1.70 0.7, 4.11 0.24
Surgery type
Conserving or none Ref Ref Ref Ref Ref
Mastectomy 0.96 0.71, 1.3 0.80 1.28 0.9, 1.82 0.17 0.84 0.58, 1.23 0.37 1.22 0.75, 2 0.43 1.43 0.94, 2.18 0.10
Treatment status
None Ref Ref Ref Ref Ref
Chemotherapy only 0.74 0.5, 1.1 0.13 0.71 0.47, 1.09 0.11 0.95 0.58, 1.54 0.83 0.55 0.29, 1.02 0.06 0.57 0.34, 0.96 0.03
Radiation only 0.99 0.67, 1.46 0.96 1.05 0.69, 1.58 0.83 0.89 0.56, 1.44 0.65 1.35 0.77, 2.35 0.29 0.93 0.57, 1.52 0.78
Both 0.58 0.36, 0.91 0.02 0.64 0.37, 1.12 0.12 0.66 0.36, 1.21 0.18 0.84 0.4, 1.74 0.63 0.84 0.44, 1.58 0.58
BMI
<25 kg/m2 Ref Ref Ref Ref Ref
25-30 kg/m2 0.85 0.65, 1.12 0.25 0.90 0.67, 1.21 0.50 0.92 0.66, 1.28 0.61 0.90 0.61, 1.34 0.61 1.10 0.77, 1.55 0.61
>30 kg/m2 1.12 0.83, 1.52 0.47 0.93 0.68, 1.29 0.67 0.88 0.61, 1.26 0.48 0.86 0.56, 1.33 0.49 0.82 0.55, 1.23 0.33
Fruit and vegetable intake
<35 servings/week Ref Ref Ref Ref Ref
≥35 servings/week 1.59 1.26, 2.02 .0001 1.06 0.82, 1.36 0.68 1.45 1.09, 1.93 0.01 1.11 0.78, 1.56 0.57 1.59 1.17, 2.16 0.003
Hrs/wk of moderate-vigorous activity
<2.5 Ref Ref Ref Ref Ref
2.5 - 5 1.15 0.84, 1.57 0.38 1.08 0.76, 1.55 0.66 1.01 0.68, 1.51 0.94 1.77 1.09, 2.87 0.02 0.74 0.47, 1.16 0.19
>5 1.20 0.91, 1.59 0.20 1.18 0.87, 1.61 0.29 1.04 0.74, 1.46 0.83 1.44 0.93, 2.23 0.11 1.07 0.74, 1.54 0.72
Smoking status
Never Ref Ref Ref Ref Ref
Ever 0.94 0.74, 1.19 0.58 1.27 0.98, 1.63 0.07 1.18 0.89, 1.58 0.26 1.25 0.89, 1.75 0.20 0.89 0.66, 1.2 0.43
aAmong Pathways participants with both baseline and 6 month follow up questionnaire.
b Comparing continuous users to non-users prior to breast cancer diagnosis.
cBeta Carotene not included in the table because insufficient number of users prior to diagnosis (n = 20).
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http://www.biomedcentral.com/1471-2407/14/382we observed high use and initiation of vitamin and min-
eral supplements in the six months following diagnosis.
The most commonly used supplements were multivita-
mins, calcium, vitamin C, and vitamin D. Only a small per-
cent of women discontinued using specific supplements
during this time. On average, the doses used by women far
exceeded the recommended intake levels by the IOM. In
our models, women who initiated supplements were gener-
ally highly educated, consumed more fruits and vegetables,
were more likely to have ever smoked cigarettes, and were
less likely to have received chemotherapy; whereas women
who discontinued were more likely to be under age 50, less
likely to have higher education, and did not undergo a
complete mastectomy. Continuous users were more likely
be older, have higher education, and consume more fruits
and vegetables. In general, supplement use was greater
among women who consumed more fruits and vegetables,
suggesting that supplement use is higher in the population
that needs supplementation the least.
Several prior studies have reported similarly high rates
of vitamin/mineral supplementation among breast cancer
patients and survivors [1,3,4,7,9-12,19,25-28]. Studies that
examined use of specific supplements describe similar
prevalence of multivitamin use, but much higher use of vi-
tamins C and E than we observed [1,4,26]. Since supple-
ment use data were collected over ten years ago for these
studies, differences may represent new recommendations
regarding antioxidant use during chemotherapy [29]. One
study reported higher rates of overall supplement use
among breast cancer survivors compared to population-
based controls [1].
In general, we report that women in the study popula-
tion were somewhat more likely to discontinue than initi-
ate supplement use. Since the commonly discontinued
supplements in this population were multivitamins and vi-
tamins C and E, we hypothesize that this difference is ex-
plained by our prospective data collection among women
while they are receiving treatment. Accordingly, a recent
report of high-risk breast cancer patients participating in a
clinical trial observed comparable changes in use during
treatment, namely decreased use of multivitamins, vitamin
C, and vitamin E, consistent use of folate, and increases in
vitamins B6 and B12 [19]. However, they did not observe
similar increases in vitamin D and calcium use, likely ex-
plained by younger participant age. The findings that differ-
ent measures of socioeconomic status (i.e., education and
income) are associated with opposite levels of use and non-
use of some of the supplements is perplexing. We think
that a main take home message from these findings is that
different constellations of factors are associated with use of
different supplements and that it is important to consider
this when interpreting dietary supplement data.
The evidence-base for use of supplements during
cancer treatment is inconsistent. Women are likelyincreasing their use of calcium and vitamin D for bone
health. Prior studies suggest that calcium and vitamin D
supplementation are safe for breast cancer patients
[14,30]. In the Pathways Study population, African
American women reported higher use of iron and vita-
min B12 before diagnosis compared to other women,
likely reflecting elevated anemia risk found in African
Americans [31]. While a single study has shown that
B12 may reduce breast cancer risk in premenopausal
women [32], and other studies have shown that iron may
promote carcinogenesis [33,34], enough data do not exist
to reach a clear consensus to infer causation about the
risks or benefits of these dietary supplements. Folic acid
and B12 are necessary to regulate DNA methylation and
prevent DNA damage, but supplementation during can-
cer treatment is controversial [35]. Chemotherapeutic
agents such as methotrexate and 5-fluorouracil disrupt
folate channels in order to promote tumor apoptosis,
and supplementation during cancer treatment has the
potential to reduce cytotoxicity [36].
Data on the effects of antioxidant use during treatment,
such as vitamin E, vitamin C, and carotenoids, are mixed.
There is concern that antioxidants during chemotherapy
and radiation therapy may reduce treatment effectiveness
[29]. One hypothesis is that antioxidant supplements may
effectively block the otherwise effective pro-oxidant therap-
ies and therefore reduce treatment effects [37]. However,
their effects on cancer outcomes remain unclear. Observa-
tional studies report inconsistent results on use of antioxi-
dants and risk of recurrence and mortality in breast cancer
patients [4,6]. Use of carotenoid supplements is of concern
because of large human trials showing increased risk of
lung cancer in those assigned to take beta-carotene [38,39].
Use of beta-carotene as an individual supplement was
not common in this population, with less than two per-
cent reporting use after diagnosis, but many women
likely use multivitamins containing beta-carotene. A re-
cent cohort study of breast cancer patients showed in-
creased risk of mortality among those taking combination
carotenoids [4] but not multivitamins [40]. Future stud-
ies utilizing information of the timing and dosage of
supplement use during treatment will help clarify
whether supplement interacts with or modifies the ef-
fect of conventional cancer treatments.
This study presents methodological improvements
over previous studies. While several prior studies were
conducted within large established cohorts, this study
specifically examined changes in behavior after diagno-
sis, distinguishing between supplement initiators and
discontinuers from continuous and never users. There-
fore, it was possible to examine changes in behavior,
which may affect survival outcomes and be especially
relevant in establishing evidence-based recommenda-
tions for patients. This study is one of the first to
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http://www.biomedcentral.com/1471-2407/14/382prospectively collect data on supplement use shortly after
diagnosis, including time during treatment. This approach
differs from many prior studies where patients were quer-
ied on their supplement use far after diagnosis. Several
previous studies were also limited by crude measurements
of supplement intake, which make it difficult to detect
small associations with cancer outcomes that are likely
confounded by lifestyle and socioeconomic factors. Here
we report detailed information on dose, allowing for com-
prehensive assessment of use patterns among continuous
users, initiators, and discontinuers.
Strengths of this study include the large population of
recently diagnosed women, an abundance of information
on supplement use and relevant covariates, and prospect-
ive data collection. However, there are limitations. First,
the participation rate in the Pathways study was 47% of
the invited sample. Thus, we cannot rule out the possibil-
ity that women who enrolled in the study were healthier
and more health conscious than those who did not enroll,
potentially biasing our results away from the null if partici-
pants are more likely to use dietary supplements than
non-participants. Differences by age and BMI at breast
cancer diagnosis were minimal when comparing the en-
rolled to unenrolled women, respectively: average age at
diagnosis 59.6 y (range: 23.6-94.8 y) vs. 61.6 y (range: 21.0-
99.8 y) and 34% obese (BMI ≥ 30 kg/m2) vs. 32%. Further,
the enrolled women appear largely representative of the
overall breast cancer population, with a slight shift to
earlier stage disease. Unenrolled women were more
likely to be African American or Asian, compared to en-
rolled women. Second, not all women completed the
6 month follow-up questionnaire. Compared to those
who completed the 6 month follow-up questionnaire,
non-completers were younger, more likely to self-report
as African American, Asian or Hispanic, had less educa-
tion, and were diagnosed with higher stage disease. As
with the non-enrollers, if the non-completers were less
health conscious than the completers, study results on
supplement use could be biased away from the null. In
addition, this study was restricted to a single geographic
region with the median education level being college
graduate, which may limit generalizability of results.
A strength of the study is the detailed assessment of sup-
plement use. Trained interviewers assessed supplement use
at baseline, whereas follow-up questionnaires were com-
pleted by participants. A prior study reported low validity
of self-report for some supplements, compared with the
gold standard of interviewer inspection of container labels
[41]. However, most of the error was derived from extract-
ing single micronutrient compositions from multivitamin
supplements and distinguishing multiple vitamins and sin-
gle supplements. A subsequent study reported high validity
and reproducibility of self-administered mailed question-
naires, compared with in-person interview, and higher self-reported intakes were linearly correlated with increasing
blood concentrations [42]. Prevalence of supplement use
prior to diagnosis may be overestimated because it was
assessed after diagnosis, and may not accurately represent
usual intake before diagnosis.
Conclusions
While previous studies have shown that breast cancer pa-
tients are very likely to use vitamin and mineral supple-
ments, we present the first large-scale study with detailed
information on changes in supplement use following diag-
nosis in a multi-ethnic population. Current guidelines for
cancer survivors recommend achieving a healthy weight;
consuming a diet high in fruits, vegetables and whole grains
while limiting processed foods and those high in saturated
fat; participating in at least 150 minutes of physical activity
per week; and not taking supplements to prevent recur-
rence [43]. A better understanding of predictors of supple-
ment initiation and discontinuation is beneficial as we
continue to examine the effects of supplement use on
breast cancer outcomes. These dietary supplements have
the potential to modify the effects of treatment on out-
comes, including breast cancer recurrence and survival.
Therefore, future studies need to test possible interactions
between supplements and treatment in order to inform
guidelines on the use of dietary supplements during breast
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